Kigen Therapeutics is developing therapeutics for chronic neuroimmune conditions that affect millions yet remain underserved by current treatments.
Founded in 2025 and based in Seoul, South Korea, we integrate advanced synthetic biology techniques with precision biomanufacturing to create novel therapeutics targeting the neuroimmune pathway.
Our work is currently in early-stage development. We look forward to sharing more details about our platform and pipeline as our work progresses.
Kigen Therapeutics is led by a team of scientists and industry professionals with expertise in neuroscience, immunology, synthetic biology, biomanufacturing, and pharmaceutical development.
Our team brings together experience from leading research and biotech backgrounds across South Korea and internationally.
